Jobs
-
Retrophin has taken several steps toward development of intranasal oxytocin for the treatment of schizophrenia and autism, the company has announced. The biopharmaceutical company says that it will acquire Kyalin Biosciences and its lead product,… Read more . . .
-
The second day of DDL 24 opened with a posters on the podium session featuring the finalists for the 2013 Pat Burnell New Investigator Award. The six presenters were: Eva Faulhammer, Technical University, Austria: “Effect… Read more . . .
-
On day 1 of DDL 24, attendees gathered in the Pentland Auditorium of the Edinburgh International Conference Centre, where they were welcomed by conference chair Gary Pitcairn. In his opening remarks, Pitcairn noted that attendance… Read more . . .
-
GlaxoSmithKline has announced that it will invest approximately £200 million in UK manufacturing sites, including a new manufacturing facility in Ware for the Relvar Ellipta dry powder inhaler. The DPI was approved in Europe in… Read more . . .
-
Evoke Pharma has appointed Marilyn Carlson as Chief Medical Officer and Wayne Alves as Senior Director of Clinical Operations. The company is planning to begin a Phase 3 clinical trial of EVK-001 intranasal metoclopramide for… Read more . . .
-
According to United Therapeutics, the Office of the Inspector General of the US Department of Health and Human Services has subpoenaed documents related to the marketing of Tyvaso trepostinil inhalation solution for the treatment of… Read more . . .
-
Savara Pharmaceuticals has announced that its AeroVanc inhaled vancomycin has received Fast Track designation from the FDA and been designated as a Qualified Infectious Disease Product (QIDP) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA)… Read more . . .
-
Acorda Therapeutics has presented data from a PK study of its diazepam nasal spray showing that dosing during seizure produces comparable pharmacokinetics to dosing immediately following a seizure. The company recently submitted an NDA for… Read more . . .
-
The European Commission (EC) has approved MedImmune’s Fluenz Tetra intranasal four-strain live attenuated influenza vaccine for the prevention of flu in children aged 24 months to 18 years, parent company AstraZeneca has announced. Fluenz Tetra… Read more . . .
-
Marinomed Biotechnologie has announced that a randomized, double-blind placebo-controlled study of more than 200 patients suffering from the common cold found that patients who received a Carragelose-based nasal spray reduced the duration of symptoms by… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA